Randomized phase II study of first-line everolimus plus bevacizumab (E+B) versus interferon α-2a plus bevacizumab (I+B) in patients (pts) with metastatic renal cell carcinoma (mRCC): Record-2 final overall survival (OS) and safety results.
Alain Ravaud
Consultant or Advisory Role - Bayer Schering Pharma; Dendreon; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Novartis; Pfizer; Roche
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Boris Y. Alekseev
No relevant relationships to disclose
Miah Hiang Tay
Honoraria - Novartis
Sanjiv S. Agarwala
No relevant relationships to disclose
Suayib Yalcin
No relevant relationships to disclose
Chia-Chi Lin
No relevant relationships to disclose
Michail Shkolnik
No relevant relationships to disclose
Vsevolod Matveev
No relevant relationships to disclose
Ozlem Anak
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Sven Gogov
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Diana Pelov
Employment or Leadership Position - Novartis
Anne-Laure Louveau
Employment or Leadership Position - Novartis
Alexandra Vaury
Employment or Leadership Position - Novartis
Bohuslav Melichar
Consultant or Advisory Role - Novartis; Roche
Honoraria - Novartis; Pfizer; Roche